News, Videos, Photos & Events
Call The Office
60 E. Sir Francis Drake Blvd. Suite 308, Larkspur, CA 94939
Latest News and Resources
COVID-19 Resource Videos
Fall Prediction & Vivacitas Healthcare
Roadmap to Pandemic Resilience with Rajiv Sethi, Divya Siddarth, and E Glen Weyl.
Unwind Your Anxiety.
Sharecare’s Unwinding Anxiety® is a step-by-step program developed by psychiatrist and neuroscientist Dr. Jud Brewer MD PhD –
The Path to Zero
Researchers and Public Health Experts unite to bring clarity to key metrics guiding coronavirus response: Harvard Global Health Institute, Harvard’s Edmond J. Safra Center for Ethics, Rockefeller Foundation, CovidActNow, Covid-Local, CIDRAP and many others join forces, launch new COVID Risk Level map and COVID suppression guidance for policy makers and the public.
Dramatic Clinical Improvement in Nine Consecutive Acutely Ill Elderly COVID-19 Patients.
Dramatic Clinical Improvement in Nine Consecutive Acutely Ill Elderly COVID-19 Patients Treated with a Nicotinamide Mononucleotide Cocktail: A Case Series
Posted: 14 Sep 2020
Cedars Sinai Medical Center
Date Written: August 17, 2020
Article URL: https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3677428
Download PDF: https://vivacitas.healthcare/wp-content/uploads/2020/09/SSRN-id3677428.pdf
Background: Nicotinamide adenine dinucleotide (NAD+) – a coenzyme found in every cell in the human body – is involved in hundreds of critical metabolic processes. However, as humans age, intracellular NAD+ levels decrease – this depletion appears to be exacerbated during complicated SARS-COV-2 infections. NAD+ depletion impairs our antiviral defense systems and our ability to optimally control inflammation.
Methods: Ten consecutive acutely-ill presumed SARS-CoV-2 infected patients older than 50 years were treated with over-the-counter nicotinamide mononucleotide (NMN), betaine, sodium chloride and zinc sulfate (NMN cocktail). Eight patients had positive nasopharyngeal SARS-CoV-2 NAA test results, one patient was clinically diagnosed with COVID-19 based on classic symptoms and one patient was excluded as COVID-19 was ruled out. The COVID-19 patients were monitored with clinical evaluations, body temperatures and room air (RA) oxygen saturation (O2 sat) levels. Serial inflammatory cytokine measurements and chest X-rays (CXRs) were done in 7/9 of the COVID-19 patients.
Results: Cases #1, 4, 7 and 10 were critically-ill with worsening O2 sats, pulmonary infiltrates and inflammation prior to administration of the NMN cocktail. Post-treatment, prompt clinical improvement was seen including fever resolution in 2-3 days (4/4), rapid CXR improvement (4/4), dramatic drops in CRP (4/4) and IL-6 (3/4) within 72 hours and hospital discharge in ≤ 5 days (3/3 cases). No patient required ICU care or intubation post treatment. Cases 5 and 8 (bilateral pneumonias but no prior CXRs) and cases 2 and 3 (symptomatic outpatients with failed trials of hydroxychloroquine (HCQ), azithromycin (AZ) and zinc (Zn) with no CXRs performed) had a strong temporal relationship between NMN cocktail use and rapid clinical improvement. Patient #6 improved with prompt fever and symptom resolution but after premature NMN cocktail discontinuation he relapsed.
Summary: The NMN cocktail resulted in rapid and dramatic clinical and laboratory improvement in older persons with complicated SARS-CoV-2 infections. NMN with and without boosters deserves further study in elderly patients with complicated COVID-19 as this treatment has a strong molecular rationale for success, can be safely administered orally at home and in critically ill hospitalized patients.
Note: Ethical Approval: Consecutive patients were enrolled in this study after signing written informed consent for study participation and for identified data being reported in a published case series on an over the counter food supplement. Thus this research is exempt under 45 CFR 46.101(b) (4) from all 45 CFR part 46 requirements and therefore does not require IRB approval. (website: https://www.hhs.gov/ohrp/regulations-and-policy/decision-charts-pre-2018-text-version/index.html#p0205)
Funding: None to declare
Declaration of Interest: None to declare
Keywords: NMN cocktail, NMN, NAD+ precursors, COVID-19, pneumonia, ARDS, hypoxia, cytokine storm
Huizenga, Robert, Dramatic Clinical Improvement in Nine Consecutive Acutely Ill Elderly COVID-19 Patients Treated with a Nicotinamide Mononucleotide Cocktail: A Case Series (August 17, 2020). Available at SSRN: https://ssrn.com/abstract=3677428
“Top 50 Healthcare Companies In The USA” By IFAH
Vivacitas Healthcare Selected For “Top 50 Healthcare Companies In The USA” By IFAH
SAN FRANCISCO, April 15, 2019 /PRNewswire/ https://vivacitas.healthcare is revolutionizing primary care for seniors in residential assisted living by creating a new clinical healthcare model that increases health outcomes, saves families time, and insurance companies millions. Vivacitas completed its 18-month pilot program with the largest senior living company in the USA and is ready to go to market nationally.
The “Top 50 Healthcare Companies in the USA,” award and distinction was bestowed upon Vivacitas after a review of 2000 leading-edge healthcare companies and candidates by the International Forum on Advancements in Healthcare.
Vivacitas provides senior living communities with onsite clinics, primary care physicians, nurse practitioners and high-tech labs – resulting in superior primary care and care coordination. The program reduced falls by seniors by up to 50 percent, reduced 911 calls and emergency room visits. Reducing falling at this percentage could save billions in the US annually and reduce stress and costs across the board for patients, families and payors such as Medicare and Medicare Advantage.
To meet exceptional demand, Vivacitas is raising substantial capital to scale operations, and expand its analytics, IP & technology portfolio.
“I’m excited and proud of what Vivacitas Healthcare has accomplished thus far. The model works and there is significant demand for Vivacitas Healthcare solutions. We will close financing and create benefits for seniors and their families nationally. The fact is, we are making a new market with integrated clinical services, analytics and IP creation. New technologies we innovate and deliver will service hundreds of millions of seniors across the globe,” said Michael Irish, Co-Founder and CEO.
“We are making the lives of our patients better in senior assisted living – falling is only one example and there are many others. By capturing lessons learned, analytics, IP and new technologies, this is the most exciting clinical model and intervention I’ve been involved in since my days in liver transplantation,” said Dr. Stephen Steady, Co-Founder and Chief Medical Director.
About Vivacitas Healthcare
Vivacitas is a technology driven healthcare solution that is radically changing the outlook for senior healthcare. Vivacitas clinics are built directly inside of assisted living communities, staffed with Doctors and Nurses skilled in elder care and equipped with state-of-the-art labs. Our staff see patients in their homes every day, which dramatically increases early intervention. And early intervention means less expensive care and more importantly, less lives lost.
Please connect now with a Vivacitas Healthcare professional so that we may walk you through your testing needs.
Call The Office
60 E. Sir Francis Drake Blvd. Suite 308, Larkspur, CA 94939